What is BridgeBio Pharma's reportable segment — R&D?

BridgeBio Pharma (BBIO) reported reportable segment — R&D of $126.64M in Q1 2026.

How has BridgeBio Pharma's reportable segment — R&D changed year-over-year?

BridgeBio Pharma's reportable segment — R&D increased by 13.6% year-over-year, from $111.43M to $126.64M.

What does reportable segment — R&D mean?

Spending on research and clinical development activities for the segment.

How do you interpret reportable segment — R&D?

Higher spending reflects aggressive pipeline investment, while lower spending may indicate project completion or cost-cutting measures.

How does reportable segment — R&D compare across companies?

Standard R&D expense reporting for biotech and pharmaceutical companies.

BridgeBio Pharma BBIO Reportable Segment — R&D

Similar metrics at other companies

BIIBReportable Segment — Research and development:

$172.8M-3.2%

NBIXReportable Segment — R&D

$296.2M+12.5%

AMGNReportable Segment — R&D

$1.72B+15.7%

KRYSReportable Segment — R&D

$15.33M+7.5%

SMMTReportable Segment — R&D

$90.2M+148%

ROIVReportable Segment — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)

$43.2M+1.1%

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's reportable segment — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's reportable segment — R&D?: BridgeBio Pharma (BBIO) reported reportable segment — R&D of $126.64M in Q1 2026.
How has BridgeBio Pharma's reportable segment — R&D changed year-over-year?: BridgeBio Pharma's reportable segment — R&D increased by 13.6% year-over-year, from $111.43M to $126.64M.
What does reportable segment — R&D mean?: Spending on research and clinical development activities for the segment.
How do you interpret reportable segment — R&D?: Higher spending reflects aggressive pipeline investment, while lower spending may indicate project completion or cost-cutting measures.
How does reportable segment — R&D compare across companies?: Standard R&D expense reporting for biotech and pharmaceutical companies.